Effects of Febuxostat for Lowering Uric Acid in NAFLD Patients With Gout

Status Not yet recruiting

Clinical Trial Summary

Nonalcoholic fatty liver disease (NAFLD) is the most common and harmful chronic liver disease. NAFLD accounts for 49.3% of the total number of chronic liver disease patients in China. It is important to effectively prevent and control NAFLD and its related diseases. Previous studies show the level of serum uric acid is significantly elevated in patients with NAFLD. Xanthine oxidase is a key enzyme in uric acid metabolism. It is a new therapeutic target for NAFLD. This study is aimed to further confirm that hyperuricemia is a new risk factor for NAFLD through a large sample prospective study. Furthermore, this study explore whether Xanthine oxidase (XO), a key enzyme in uric acid metabolism, plays an important role in regulating NAFLD.

Clinical Trial Description

Nonalcoholic fatty liver disease (NAFLD) is the most common and harmful chronic liver disease. NAFLD accounts for 49.3% of the total number of chronic liver disease patients in China. It is important to effectively prevent and control NAFLD and its related diseases. Previous studies show the level of serum uric acid is significantly elevated in patients with NAFLD. In a large cross-sectional study, the researcher were the first to confirm that serum uric acid level was significantly increased in patients with NAFLD. The results were published in J Hepatol. Xanthine oxidase is a key enzyme in uric acid metabolism. It is a new therapeutic target for NAFLD. This study is aimed to further confirm that hyperuricemia is a new risk factor for NAFLD through a large sample prospective study. Furthermore, this study explore whether Xanthine oxidase (XO), a key enzyme in uric acid metabolism, plays an important role in regulating NAFLD. ;

Study Design

Related Conditions & MeSH terms

Fatty Liver
Liver Diseases
Non-alcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver Disease

Clinical Trial Details

NCT number	NCT04772352
Study type	Interventional
Source	Ningbo No. 1 Hospital
Contact
Status	Not yet recruiting
Phase	Phase 2
Start date	March 1, 2021
Completion date	March 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT06138327` - A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria	Phase 1
Completed	`NCT01045499` - LAGB as a Treatment for Morbid Obesity in Adolescents	N/A
Completed	`NCT03674476` - An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function	Phase 1
Not yet recruiting	`NCT05495139` - Gastric Bypass Stent Small-Sample-Size Study For Nonalcoholic Fatty Liver Disease	N/A
Completed	`NCT04988204` - Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease	N/A
Recruiting	`NCT04369521` - Evaluation of the Effects of a Low Free Sugar Diet in Patients With Nonalcoholic Fatty Liver Disease	N/A
Completed	`NCT01934777` - Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis	Phase 3
Enrolling by invitation	`NCT00983463` - Abundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)
Recruiting	`NCT00658164` - Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores	Phase 3
Recruiting	`NCT02148471` - Fatty Acids, Genes and Microbiota in Fatty Liver	N/A
Completed	`NCT06441409` - Serum Ferritin Levels and Metabolic Dysfunction Associated Steatotic Liver Disease	N/A
Completed	`NCT03656744` - A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)	Phase 2
Not yet recruiting	`NCT01735799` - THE ASSOCIATION BETWEEN FATTY LIVER (NAFLD) DISEASE AND PCOS	N/A
Completed	`NCT01446276` - Long-term Investigation of Resveratrol on Fat Metabolism in Obese Men With Nonalcoholic Fatty Liver Disease	N/A
Completed	`NCT00930384` - A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis	N/A
Recruiting	`NCT02469272` - Fecal Microbiota Transplantation (FMT) in Nonalcoholic Steatohepatitis(NASH). A Pilot Study	Phase 1
Completed	`NCT02132780` - Autonomic Dysfunction in Non-Alcoholic Fatty Liver Disease	N/A
Completed	`NCT01399645` - Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes	Phase 2
Terminated	`NCT01355575` - Rifaximin in Fatty Liver Disease	Phase 4
Completed	`NCT01210989` - Trial of Hepaguard® in Adults With Nonalcoholic Steatohepatitis	N/A